Global New Drug Development Global New Drug Development
Postgraduate Pharmacy Series

Global New Drug Development

An Introduction

Jan A. Rosier and Others
    • $104.99
    • $104.99

Publisher Description

The development of new drugs is very complex, costly and risky. Its success is highly dependent on an intense collaboration and interaction between many departments within the drug development organization, external investigators and service providers, in constant dialogue with regulatory authorities, payers, academic experts, clinicians and patient organizations. Within the different phases of the drug life cycle, drug development is by far the most crucial part for the initial and continued success of a drug on the market.

This book offers an introduction to the field of drug development with a clear overview of the different processes that lead to a successful new medicine and of the regulatory pathways that are used to launch a new drug that are both safe and efficacious.

"This is the most comprehensive and detailed book on drug development I have ever read and I feel that it is likely to become a staple of drug development courses, such as those taught at Masters Level in my own University.... I think in the light of increasing integration of company and academic approaches to drug development both sides can read this book... (and, therefore)... this book could not be more timely."
Professor Mike Coleman, University of Aston, UK ( from his review of the final manuscript)

GENRE
Professional & Technical
RELEASED
2014
3 July
LANGUAGE
EN
English
LENGTH
424
Pages
PUBLISHER
Wiley
SELLER
John Wiley & Sons Australia, Ltd
SIZE
8.7
MB

More Books Like This

Principles of Biomedical Sciences and Industry Principles of Biomedical Sciences and Industry
2022
The Role of the Study Director in Nonclinical Studies The Role of the Study Director in Nonclinical Studies
2014
Practical Handbook of Clinical Investigation Practical Handbook of Clinical Investigation
2016
The FDA should Not Mandate Comparative-Effectiveness Trials (Health Policy Outlook) The FDA should Not Mandate Comparative-Effectiveness Trials (Health Policy Outlook)
2011
Value Creation in the Pharmaceutical Industry Value Creation in the Pharmaceutical Industry
2016
Supporting Pharmaceutical Studies for FDA Submissions: Diversifying the Drug Monitoring Laboratory (Tdm Conference) Supporting Pharmaceutical Studies for FDA Submissions: Diversifying the Drug Monitoring Laboratory (Tdm Conference)
1998

Other Books in This Series

Ethnopharmacology Ethnopharmacology
2015
Inhalation Drug Delivery Inhalation Drug Delivery
2012